Ontology type: schema:ScholarlyArticle Open Access: True
2016-08-04
AUTHORSK K McLaurin, A M Farr, S W Wade, D R Diakun, D L Stewart
ABSTRACTObjective:Infection with respiratory syncytial virus (RSV), which causes lower respiratory tract infections, is the leading cause of hospitalization among children <1 year old in the United States. Risk factors for RSV hospitalization include premature birth and younger chronologic age, along with several comorbid conditions. However, in terms of RSV hospitalization costs, premature infants are rarely studied separately from full-term infants. The objective of this study is to describe the cost and severity of RSV hospitalizations among preterm and full-term infants without chronic lung disease or other high-risk conditions.Study Design:This analysis used Truven Health Market Scan Multi-State Medicaid and Commercial Claims and Encounters databases, which contain a combined 4 million births from 2003 to 2013. Infants with comorbid conditions associated with increased risk for RSV infection were excluded. Infants were classified as preterm (<29, 29−30, 31−32, 33−34 and 35−36 weeks’ gestational age (wGA)) or full term based on diagnostic coding. Health-care claims during the first year of life were evaluated for RSV hospitalizations, defined as inpatient claims with a diagnosis code for RSV in any position. Costs of RSV hospitalizations were captured and reported in 2014 USD. Inpatient claims for RSV hospitalizations were evaluated for the presence of codes indicating admission to the intensive care unit (ICU), use of mechanical ventilation (MV) and length of stay. These three measures were used to describe hospital severity. Chronologic age at the time of RSV hospitalization was also captured. Data were summarized and no statistical comparisons were conducted.Results:There were 1 683 188 infants insured through Medicaid and 1 663 832 infants insured through commercial plans born from 1 July 2003 to 30 June 2013. Of those, 10.8 and 8.8% in each database, respectively, were born prematurely. There were 29 967 Medicaid-insured infants and 16 310 commercially insured infants with an RSV hospitalization during their first year of life. Mean first-year RSV hospitalization costs were higher for preterm infants, ranging from $8324 and $10 570 for full-term infants to $15 839 and $19 931 for preterm infants 33–34 wGA, and to $39 354 and $40 813 for preterm infants <29 wGA, among Medicaid-insured and commercially insured infants, respectively. RSV hospitalizations also tended to be more severe among preterm infants, with longer lengths of stay, a higher proportion of infants admitted to the intensive care unit (ICU) and increased use of MV compared with full-term infants. Mean costs of RSV hospitalizations with a PICU admission ranged from approximately $35 000 to $89 000. In both Medicaid and commercial groups, costs were greater for infants hospitalized at <90 days of age compared with older infants.Conclusions:Infants who were born prematurely and those hospitalized at <90 days of age have more costly and more severe RSV hospitalizations during the first year of life. These findings demonstrate important differences in the costs and severity of first-year RSV hospitalizations of premature and full-term infants. These differences are likely to be obscured in combined analysis, in which full-term infants predominate. Clinical guidelines and health-care policies relating to RSV would benefit from the availability of data obtained from separate analyses of these two infant subgroups. More... »
PAGES990-996
http://scigraph.springernature.com/pub.10.1038/jp.2016.113
DOIhttp://dx.doi.org/10.1038/jp.2016.113
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1007747632
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/27490190
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1114",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Paediatrics and Reproductive Medicine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Age Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Databases, Factual",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gestational Age",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hospitalization",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infant",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infant, Newborn",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infant, Premature",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Insurance, Health",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Intensive Care Units, Neonatal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Length of Stay",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Medicaid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Respiratory Syncytial Virus Infections",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risk Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Severity of Illness Index",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "United States",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Health Economics and Outcomes Research, Medical Affairs, AstraZeneca, Gaithersburg, MD, USA",
"id": "http://www.grid.ac/institutes/grid.418152.b",
"name": [
"Health Economics and Outcomes Research, Medical Affairs, AstraZeneca, Gaithersburg, MD, USA"
],
"type": "Organization"
},
"familyName": "McLaurin",
"givenName": "K K",
"id": "sg:person.01116472424.97",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116472424.97"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Life Sciences, Truven Health Analytics an IBM Company, Cambridge, MA, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Life Sciences, Truven Health Analytics an IBM Company, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Farr",
"givenName": "A M",
"id": "sg:person.014011544305.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014011544305.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Wade Outcomes Research and Consulting, Salt Lake City, UT, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Wade Outcomes Research and Consulting, Salt Lake City, UT, USA"
],
"type": "Organization"
},
"familyName": "Wade",
"givenName": "S W",
"id": "sg:person.0617012057.00",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Life Sciences, Truven Health Analytics, an IBM Company, Bethesda, MD, USA",
"id": "http://www.grid.ac/institutes/grid.460065.1",
"name": [
"Life Sciences, Truven Health Analytics, an IBM Company, Bethesda, MD, USA"
],
"type": "Organization"
},
"familyName": "Diakun",
"givenName": "D R",
"id": "sg:person.015404505305.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015404505305.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pediatrics, University of Louisville School of Medicine, University of Louisville Hospital, Kosair Children\u2019s Hospital, Louisville, KY, USA",
"id": "http://www.grid.ac/institutes/grid.413750.4",
"name": [
"Department of Pediatrics, University of Louisville School of Medicine, University of Louisville Hospital, Kosair Children\u2019s Hospital, Louisville, KY, USA"
],
"type": "Organization"
},
"familyName": "Stewart",
"givenName": "D L",
"type": "Person"
}
],
"datePublished": "2016-08-04",
"datePublishedReg": "2016-08-04",
"description": "Objective:Infection with respiratory syncytial virus (RSV), which causes lower respiratory tract infections, is the leading cause of hospitalization among children <1 year old in the United States. Risk factors for RSV hospitalization include premature birth and younger chronologic age, along with several comorbid conditions. However, in terms of RSV hospitalization costs, premature infants are rarely studied separately from full-term infants. The objective of this study is to describe the cost and severity of RSV hospitalizations among preterm and full-term infants without chronic lung disease or other high-risk conditions.Study Design:This analysis used Truven Health Market Scan Multi-State Medicaid and Commercial Claims and Encounters databases, which contain a combined 4 million births from 2003 to 2013. Infants with comorbid conditions associated with increased risk for RSV infection were excluded. Infants were classified as preterm (<29, 29\u221230, 31\u221232, 33\u221234 and 35\u221236 weeks\u2019 gestational age (wGA)) or full term based on diagnostic coding. Health-care claims during the first year of life were evaluated for RSV hospitalizations, defined as inpatient claims with a diagnosis code for RSV in any position. Costs of RSV hospitalizations were captured and reported in 2014 USD. Inpatient claims for RSV hospitalizations were evaluated for the presence of codes indicating admission to the intensive care unit (ICU), use of mechanical ventilation (MV) and length of stay. These three measures were used to describe hospital severity. Chronologic age at the time of RSV hospitalization was also captured. Data were summarized and no statistical comparisons were conducted.Results:There were 1\u2009683\u2009188 infants insured through Medicaid and 1\u2009663\u2009832 infants insured through commercial plans born from 1 July 2003 to 30 June 2013. Of those, 10.8 and 8.8% in each database, respectively, were born prematurely. There were 29\u2009967 Medicaid-insured infants and 16\u2009310 commercially insured infants with an RSV hospitalization during their first year of life. Mean first-year RSV hospitalization costs were higher for preterm infants, ranging from $8324 and $10\u2009570 for full-term infants to $15\u2009839 and $19\u2009931 for preterm infants 33\u201334 wGA, and to $39\u2009354 and $40\u2009813 for preterm infants <29 wGA, among Medicaid-insured and commercially insured infants, respectively. RSV hospitalizations also tended to be more severe among preterm infants, with longer lengths of stay, a higher proportion of infants admitted to the intensive care unit (ICU) and increased use of MV compared with full-term infants. Mean costs of RSV hospitalizations with a PICU admission ranged from approximately $35\u2009000 to $89\u2009000. In both Medicaid and commercial groups, costs were greater for infants hospitalized at <90 days of age compared with older infants.Conclusions:Infants who were born prematurely and those hospitalized at <90 days of age have more costly and more severe RSV hospitalizations during the first year of life. These findings demonstrate important differences in the costs and severity of first-year RSV hospitalizations of premature and full-term infants. These differences are likely to be obscured in combined analysis, in which full-term infants predominate. Clinical guidelines and health-care policies relating to RSV would benefit from the availability of data obtained from separate analyses of these two infant subgroups.",
"genre": "article",
"id": "sg:pub.10.1038/jp.2016.113",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1095220",
"issn": [
"0743-8346",
"1476-5543"
],
"name": "Journal of Perinatology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "11",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "36"
}
],
"keywords": [
"full-term infants",
"intensive care unit",
"respiratory syncytial virus",
"RSV hospitalization",
"preterm infants",
"mechanical ventilation",
"days of age",
"comorbid conditions",
"care unit",
"hospitalization costs",
"inpatient claims",
"chronologic age",
"use of MV",
"lower respiratory tract infections",
"Multi-State Medicaid",
"preterm infants 33",
"respiratory tract infections",
"cause of hospitalization",
"chronic lung disease",
"length of stay",
"first year",
"younger chronologic age",
"high-risk conditions",
"health care claims",
"health care policy",
"hospital severity",
"infants 33",
"PICU admission",
"tract infections",
"RSV infection",
"premature infants",
"syncytial virus",
"premature birth",
"infant subgroups",
"hospitalization outcomes",
"lung disease",
"Encounters Database",
"diagnosis codes",
"risk factors",
"clinical guidelines",
"Commercial Claims",
"hospitalization",
"full term",
"mean cost",
"diagnostic coding",
"infants",
"older infants",
"Medicaid",
"infection",
"severity",
"commercial plans",
"preterm",
"age",
"longer length",
"admission",
"stay",
"higher proportion",
"birth",
"separate analysis",
"years",
"days",
"statistical comparison",
"important differences",
"disease",
"ventilation",
"life",
"outcomes",
"virus",
"United States",
"subgroups",
"differences",
"children",
"risk",
"database",
"presence of code",
"cause",
"guidelines",
"group",
"proportion",
"findings",
"use",
"factors",
"data",
"analysis",
"study",
"units",
"measures",
"commercial groups",
"length",
"presence",
"objective",
"conditions",
"plan",
"availability of data",
"time",
"USD",
"comparison",
"cost",
"availability",
"claims",
"terms",
"state",
"position",
"policy",
"coding",
"code"
],
"name": "Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants",
"pagination": "990-996",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1007747632"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/jp.2016.113"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"27490190"
]
}
],
"sameAs": [
"https://doi.org/10.1038/jp.2016.113",
"https://app.dimensions.ai/details/publication/pub.1007747632"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:31",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_684.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/jp.2016.113"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/jp.2016.113'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/jp.2016.113'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/jp.2016.113'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/jp.2016.113'
This table displays all metadata directly associated to this object as RDF triples.
278 TRIPLES
21 PREDICATES
150 URIs
142 LITERALS
25 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1038/jp.2016.113 | schema:about | N0c1d29a24be34753929a4b52551f5494 |
2 | ″ | ″ | N15aa6ee9053041599f913744adf79a72 |
3 | ″ | ″ | N1dd576c8133a411f97df2e17a66bc776 |
4 | ″ | ″ | N25e342826cfd4a7d890f9aba4cef3b63 |
5 | ″ | ″ | N452fb81cd15946fdbef6922ca78cfc73 |
6 | ″ | ″ | N74a904d137e74216a5a014a5166b9b21 |
7 | ″ | ″ | N752debd4a4024b56b0ae8deff68ba3ed |
8 | ″ | ″ | N7d9d751871bd42078a630e4eaae6adc7 |
9 | ″ | ″ | N8b185afdfedf40a3aa085e4672fabfd8 |
10 | ″ | ″ | N991c5955f1e0410fa061a9ff95995294 |
11 | ″ | ″ | Nc7c34e500d1b4dd4a27814f9d9f98fb8 |
12 | ″ | ″ | Ncb55451a3af14a25862c921b7a19a089 |
13 | ″ | ″ | Ncc9b65d2eea24197acd38b90064a888b |
14 | ″ | ″ | Ndcff1664fba942d0a9241fdb6b645353 |
15 | ″ | ″ | Ndf7f2d407a574b5bb16b7123a1c2ad7a |
16 | ″ | ″ | Ne6c20ff99adf40578a6c68db2414112c |
17 | ″ | ″ | Ned4fe39daca54727ad71cb3c7c19f849 |
18 | ″ | ″ | Nf8acf43169a644ab9b625a46d5ec38b4 |
19 | ″ | ″ | anzsrc-for:11 |
20 | ″ | ″ | anzsrc-for:1114 |
21 | ″ | schema:author | Nfd109e711cb34e9488c8081d0e5bb4fa |
22 | ″ | schema:datePublished | 2016-08-04 |
23 | ″ | schema:datePublishedReg | 2016-08-04 |
24 | ″ | schema:description | Objective:Infection with respiratory syncytial virus (RSV), which causes lower respiratory tract infections, is the leading cause of hospitalization among children <1 year old in the United States. Risk factors for RSV hospitalization include premature birth and younger chronologic age, along with several comorbid conditions. However, in terms of RSV hospitalization costs, premature infants are rarely studied separately from full-term infants. The objective of this study is to describe the cost and severity of RSV hospitalizations among preterm and full-term infants without chronic lung disease or other high-risk conditions.Study Design:This analysis used Truven Health Market Scan Multi-State Medicaid and Commercial Claims and Encounters databases, which contain a combined 4 million births from 2003 to 2013. Infants with comorbid conditions associated with increased risk for RSV infection were excluded. Infants were classified as preterm (<29, 29−30, 31−32, 33−34 and 35−36 weeks’ gestational age (wGA)) or full term based on diagnostic coding. Health-care claims during the first year of life were evaluated for RSV hospitalizations, defined as inpatient claims with a diagnosis code for RSV in any position. Costs of RSV hospitalizations were captured and reported in 2014 USD. Inpatient claims for RSV hospitalizations were evaluated for the presence of codes indicating admission to the intensive care unit (ICU), use of mechanical ventilation (MV) and length of stay. These three measures were used to describe hospital severity. Chronologic age at the time of RSV hospitalization was also captured. Data were summarized and no statistical comparisons were conducted.Results:There were 1 683 188 infants insured through Medicaid and 1 663 832 infants insured through commercial plans born from 1 July 2003 to 30 June 2013. Of those, 10.8 and 8.8% in each database, respectively, were born prematurely. There were 29 967 Medicaid-insured infants and 16 310 commercially insured infants with an RSV hospitalization during their first year of life. Mean first-year RSV hospitalization costs were higher for preterm infants, ranging from $8324 and $10 570 for full-term infants to $15 839 and $19 931 for preterm infants 33–34 wGA, and to $39 354 and $40 813 for preterm infants <29 wGA, among Medicaid-insured and commercially insured infants, respectively. RSV hospitalizations also tended to be more severe among preterm infants, with longer lengths of stay, a higher proportion of infants admitted to the intensive care unit (ICU) and increased use of MV compared with full-term infants. Mean costs of RSV hospitalizations with a PICU admission ranged from approximately $35 000 to $89 000. In both Medicaid and commercial groups, costs were greater for infants hospitalized at <90 days of age compared with older infants.Conclusions:Infants who were born prematurely and those hospitalized at <90 days of age have more costly and more severe RSV hospitalizations during the first year of life. These findings demonstrate important differences in the costs and severity of first-year RSV hospitalizations of premature and full-term infants. These differences are likely to be obscured in combined analysis, in which full-term infants predominate. Clinical guidelines and health-care policies relating to RSV would benefit from the availability of data obtained from separate analyses of these two infant subgroups. |
25 | ″ | schema:genre | article |
26 | ″ | schema:inLanguage | en |
27 | ″ | schema:isAccessibleForFree | true |
28 | ″ | schema:isPartOf | N0f69ec971ee749f5955a8ef3ab708a9b |
29 | ″ | ″ | N63c6292195ba45e1b5c2f78ffb9cd54a |
30 | ″ | ″ | sg:journal.1095220 |
31 | ″ | schema:keywords | Commercial Claims |
32 | ″ | ″ | Encounters Database |
33 | ″ | ″ | Medicaid |
34 | ″ | ″ | Multi-State Medicaid |
35 | ″ | ″ | PICU admission |
36 | ″ | ″ | RSV hospitalization |
37 | ″ | ″ | RSV infection |
38 | ″ | ″ | USD |
39 | ″ | ″ | United States |
40 | ″ | ″ | admission |
41 | ″ | ″ | age |
42 | ″ | ″ | analysis |
43 | ″ | ″ | availability |
44 | ″ | ″ | availability of data |
45 | ″ | ″ | birth |
46 | ″ | ″ | care unit |
47 | ″ | ″ | cause |
48 | ″ | ″ | cause of hospitalization |
49 | ″ | ″ | children |
50 | ″ | ″ | chronic lung disease |
51 | ″ | ″ | chronologic age |
52 | ″ | ″ | claims |
53 | ″ | ″ | clinical guidelines |
54 | ″ | ″ | code |
55 | ″ | ″ | coding |
56 | ″ | ″ | commercial groups |
57 | ″ | ″ | commercial plans |
58 | ″ | ″ | comorbid conditions |
59 | ″ | ″ | comparison |
60 | ″ | ″ | conditions |
61 | ″ | ″ | cost |
62 | ″ | ″ | data |
63 | ″ | ″ | database |
64 | ″ | ″ | days |
65 | ″ | ″ | days of age |
66 | ″ | ″ | diagnosis codes |
67 | ″ | ″ | diagnostic coding |
68 | ″ | ″ | differences |
69 | ″ | ″ | disease |
70 | ″ | ″ | factors |
71 | ″ | ″ | findings |
72 | ″ | ″ | first year |
73 | ″ | ″ | full term |
74 | ″ | ″ | full-term infants |
75 | ″ | ″ | group |
76 | ″ | ″ | guidelines |
77 | ″ | ″ | health care claims |
78 | ″ | ″ | health care policy |
79 | ″ | ″ | high-risk conditions |
80 | ″ | ″ | higher proportion |
81 | ″ | ″ | hospital severity |
82 | ″ | ″ | hospitalization |
83 | ″ | ″ | hospitalization costs |
84 | ″ | ″ | hospitalization outcomes |
85 | ″ | ″ | important differences |
86 | ″ | ″ | infant subgroups |
87 | ″ | ″ | infants |
88 | ″ | ″ | infants 33 |
89 | ″ | ″ | infection |
90 | ″ | ″ | inpatient claims |
91 | ″ | ″ | intensive care unit |
92 | ″ | ″ | length |
93 | ″ | ″ | length of stay |
94 | ″ | ″ | life |
95 | ″ | ″ | longer length |
96 | ″ | ″ | lower respiratory tract infections |
97 | ″ | ″ | lung disease |
98 | ″ | ″ | mean cost |
99 | ″ | ″ | measures |
100 | ″ | ″ | mechanical ventilation |
101 | ″ | ″ | objective |
102 | ″ | ″ | older infants |
103 | ″ | ″ | outcomes |
104 | ″ | ″ | plan |
105 | ″ | ″ | policy |
106 | ″ | ″ | position |
107 | ″ | ″ | premature birth |
108 | ″ | ″ | premature infants |
109 | ″ | ″ | presence |
110 | ″ | ″ | presence of code |
111 | ″ | ″ | preterm |
112 | ″ | ″ | preterm infants |
113 | ″ | ″ | preterm infants 33 |
114 | ″ | ″ | proportion |
115 | ″ | ″ | respiratory syncytial virus |
116 | ″ | ″ | respiratory tract infections |
117 | ″ | ″ | risk |
118 | ″ | ″ | risk factors |
119 | ″ | ″ | separate analysis |
120 | ″ | ″ | severity |
121 | ″ | ″ | state |
122 | ″ | ″ | statistical comparison |
123 | ″ | ″ | stay |
124 | ″ | ″ | study |
125 | ″ | ″ | subgroups |
126 | ″ | ″ | syncytial virus |
127 | ″ | ″ | terms |
128 | ″ | ″ | time |
129 | ″ | ″ | tract infections |
130 | ″ | ″ | units |
131 | ″ | ″ | use |
132 | ″ | ″ | use of MV |
133 | ″ | ″ | ventilation |
134 | ″ | ″ | virus |
135 | ″ | ″ | years |
136 | ″ | ″ | younger chronologic age |
137 | ″ | schema:name | Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants |
138 | ″ | schema:pagination | 990-996 |
139 | ″ | schema:productId | N69c176e911784fb182ece56a9ffdef9b |
140 | ″ | ″ | N9e9f8d3bf329436585e4212ae803ff35 |
141 | ″ | ″ | Naf7d44cf3a5d4e49985e03a8e96966da |
142 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1007747632 |
143 | ″ | ″ | https://doi.org/10.1038/jp.2016.113 |
144 | ″ | schema:sdDatePublished | 2022-05-20T07:31 |
145 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
146 | ″ | schema:sdPublisher | N97863311262940a1abbc8ae36f9cfb4f |
147 | ″ | schema:url | https://doi.org/10.1038/jp.2016.113 |
148 | ″ | sgo:license | sg:explorer/license/ |
149 | ″ | sgo:sdDataset | articles |
150 | ″ | rdf:type | schema:ScholarlyArticle |
151 | N0c1d29a24be34753929a4b52551f5494 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
152 | ″ | schema:name | Male |
153 | ″ | rdf:type | schema:DefinedTerm |
154 | N0f69ec971ee749f5955a8ef3ab708a9b | schema:issueNumber | 11 |
155 | ″ | rdf:type | schema:PublicationIssue |
156 | N0ff3f69b4f044dae9dbf8a5f2f7ac931 | rdf:first | Nc776098ca15f4a6583eeb93e784d556e |
157 | ″ | rdf:rest | rdf:nil |
158 | N15aa6ee9053041599f913744adf79a72 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
159 | ″ | schema:name | Medicaid |
160 | ″ | rdf:type | schema:DefinedTerm |
161 | N1dd576c8133a411f97df2e17a66bc776 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
162 | ″ | schema:name | United States |
163 | ″ | rdf:type | schema:DefinedTerm |
164 | N25e342826cfd4a7d890f9aba4cef3b63 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
165 | ″ | schema:name | Length of Stay |
166 | ″ | rdf:type | schema:DefinedTerm |
167 | N452fb81cd15946fdbef6922ca78cfc73 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
168 | ″ | schema:name | Insurance, Health |
169 | ″ | rdf:type | schema:DefinedTerm |
170 | N63c6292195ba45e1b5c2f78ffb9cd54a | schema:volumeNumber | 36 |
171 | ″ | rdf:type | schema:PublicationVolume |
172 | N69c176e911784fb182ece56a9ffdef9b | schema:name | doi |
173 | ″ | schema:value | 10.1038/jp.2016.113 |
174 | ″ | rdf:type | schema:PropertyValue |
175 | N74a904d137e74216a5a014a5166b9b21 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
176 | ″ | schema:name | Gestational Age |
177 | ″ | rdf:type | schema:DefinedTerm |
178 | N752debd4a4024b56b0ae8deff68ba3ed | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
179 | ″ | schema:name | Intensive Care Units, Neonatal |
180 | ″ | rdf:type | schema:DefinedTerm |
181 | N79b679acdcf546e69e5c0561b68ae77e | rdf:first | sg:person.014011544305.49 |
182 | ″ | rdf:rest | Nebcf8191669a46328abeafb3af853e26 |
183 | N7d9d751871bd42078a630e4eaae6adc7 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
184 | ″ | schema:name | Databases, Factual |
185 | ″ | rdf:type | schema:DefinedTerm |
186 | N8b185afdfedf40a3aa085e4672fabfd8 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
187 | ″ | schema:name | Humans |
188 | ″ | rdf:type | schema:DefinedTerm |
189 | N97863311262940a1abbc8ae36f9cfb4f | schema:name | Springer Nature - SN SciGraph project |
190 | ″ | rdf:type | schema:Organization |
191 | N991c5955f1e0410fa061a9ff95995294 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
192 | ″ | schema:name | Respiratory Syncytial Virus Infections |
193 | ″ | rdf:type | schema:DefinedTerm |
194 | N9e9f8d3bf329436585e4212ae803ff35 | schema:name | pubmed_id |
195 | ″ | schema:value | 27490190 |
196 | ″ | rdf:type | schema:PropertyValue |
197 | Naf7d44cf3a5d4e49985e03a8e96966da | schema:name | dimensions_id |
198 | ″ | schema:value | pub.1007747632 |
199 | ″ | rdf:type | schema:PropertyValue |
200 | Nc776098ca15f4a6583eeb93e784d556e | schema:affiliation | grid-institutes:grid.413750.4 |
201 | ″ | schema:familyName | Stewart |
202 | ″ | schema:givenName | D L |
203 | ″ | rdf:type | schema:Person |
204 | Nc7c34e500d1b4dd4a27814f9d9f98fb8 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
205 | ″ | schema:name | Infant, Newborn |
206 | ″ | rdf:type | schema:DefinedTerm |
207 | Ncb55451a3af14a25862c921b7a19a089 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
208 | ″ | schema:name | Infant, Premature |
209 | ″ | rdf:type | schema:DefinedTerm |
210 | Ncc9b65d2eea24197acd38b90064a888b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
211 | ″ | schema:name | Severity of Illness Index |
212 | ″ | rdf:type | schema:DefinedTerm |
213 | Ndcff1664fba942d0a9241fdb6b645353 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
214 | ″ | schema:name | Female |
215 | ″ | rdf:type | schema:DefinedTerm |
216 | Ndf7f2d407a574b5bb16b7123a1c2ad7a | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
217 | ″ | schema:name | Risk Factors |
218 | ″ | rdf:type | schema:DefinedTerm |
219 | Ne60c48ff2c5f48dd8279d0db0bfc9aed | rdf:first | sg:person.015404505305.76 |
220 | ″ | rdf:rest | N0ff3f69b4f044dae9dbf8a5f2f7ac931 |
221 | Ne6c20ff99adf40578a6c68db2414112c | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
222 | ″ | schema:name | Infant |
223 | ″ | rdf:type | schema:DefinedTerm |
224 | Nebcf8191669a46328abeafb3af853e26 | rdf:first | sg:person.0617012057.00 |
225 | ″ | rdf:rest | Ne60c48ff2c5f48dd8279d0db0bfc9aed |
226 | Ned4fe39daca54727ad71cb3c7c19f849 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
227 | ″ | schema:name | Age Factors |
228 | ″ | rdf:type | schema:DefinedTerm |
229 | Nf8acf43169a644ab9b625a46d5ec38b4 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
230 | ″ | schema:name | Hospitalization |
231 | ″ | rdf:type | schema:DefinedTerm |
232 | Nfd109e711cb34e9488c8081d0e5bb4fa | rdf:first | sg:person.01116472424.97 |
233 | ″ | rdf:rest | N79b679acdcf546e69e5c0561b68ae77e |
234 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
235 | ″ | schema:name | Medical and Health Sciences |
236 | ″ | rdf:type | schema:DefinedTerm |
237 | anzsrc-for:1114 | schema:inDefinedTermSet | anzsrc-for: |
238 | ″ | schema:name | Paediatrics and Reproductive Medicine |
239 | ″ | rdf:type | schema:DefinedTerm |
240 | sg:journal.1095220 | schema:issn | 0743-8346 |
241 | ″ | ″ | 1476-5543 |
242 | ″ | schema:name | Journal of Perinatology |
243 | ″ | schema:publisher | Springer Nature |
244 | ″ | rdf:type | schema:Periodical |
245 | sg:person.01116472424.97 | schema:affiliation | grid-institutes:grid.418152.b |
246 | ″ | schema:familyName | McLaurin |
247 | ″ | schema:givenName | K K |
248 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116472424.97 |
249 | ″ | rdf:type | schema:Person |
250 | sg:person.014011544305.49 | schema:affiliation | grid-institutes:None |
251 | ″ | schema:familyName | Farr |
252 | ″ | schema:givenName | A M |
253 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014011544305.49 |
254 | ″ | rdf:type | schema:Person |
255 | sg:person.015404505305.76 | schema:affiliation | grid-institutes:grid.460065.1 |
256 | ″ | schema:familyName | Diakun |
257 | ″ | schema:givenName | D R |
258 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015404505305.76 |
259 | ″ | rdf:type | schema:Person |
260 | sg:person.0617012057.00 | schema:affiliation | grid-institutes:None |
261 | ″ | schema:familyName | Wade |
262 | ″ | schema:givenName | S W |
263 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00 |
264 | ″ | rdf:type | schema:Person |
265 | grid-institutes:None | schema:alternateName | Life Sciences, Truven Health Analytics an IBM Company, Cambridge, MA, USA |
266 | ″ | ″ | Wade Outcomes Research and Consulting, Salt Lake City, UT, USA |
267 | ″ | schema:name | Life Sciences, Truven Health Analytics an IBM Company, Cambridge, MA, USA |
268 | ″ | ″ | Wade Outcomes Research and Consulting, Salt Lake City, UT, USA |
269 | ″ | rdf:type | schema:Organization |
270 | grid-institutes:grid.413750.4 | schema:alternateName | Department of Pediatrics, University of Louisville School of Medicine, University of Louisville Hospital, Kosair Children’s Hospital, Louisville, KY, USA |
271 | ″ | schema:name | Department of Pediatrics, University of Louisville School of Medicine, University of Louisville Hospital, Kosair Children’s Hospital, Louisville, KY, USA |
272 | ″ | rdf:type | schema:Organization |
273 | grid-institutes:grid.418152.b | schema:alternateName | Health Economics and Outcomes Research, Medical Affairs, AstraZeneca, Gaithersburg, MD, USA |
274 | ″ | schema:name | Health Economics and Outcomes Research, Medical Affairs, AstraZeneca, Gaithersburg, MD, USA |
275 | ″ | rdf:type | schema:Organization |
276 | grid-institutes:grid.460065.1 | schema:alternateName | Life Sciences, Truven Health Analytics, an IBM Company, Bethesda, MD, USA |
277 | ″ | schema:name | Life Sciences, Truven Health Analytics, an IBM Company, Bethesda, MD, USA |
278 | ″ | rdf:type | schema:Organization |